AstraZeneca shares tumble after lung cancer treatment fails to meet expectations
Pharmaceutical giant AstraZeneca has seen its share price plunge significantly, down 5%, following the release of less favorable results from a major lung cancer drug clinical trial. This development has raised concerns among investors and stakeholders about the future prospects of the company's oncology pipeline. AstraZeneca has been at the forefront of developing innovative treatments for various types of cancer, and this particular drug was expected to be a major breakthrough in lung cancer treatment. However, the trial results did not meet the high expectations set by earlier phases of testing, causing a strong reaction in the stock market. The…




